about
Individualised treatment of proliferative diabetic retinopathy: optimal surgical timing improves long-term outcomes.Criteria for creating and assessing mouse models of diabetic neuropathy.Hypoxia and the expression of HIF-1alpha and HIF-2alpha in the retina of streptozotocin-injected mice and ratsModulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology.Automated detection of proliferative retinopathy in clinical practiceImbalance of the nerve growth factor and its precursor as a potential biomarker for diabetic retinopathy.Reversal of the Caspase-Dependent Apoptotic Cytotoxicity Pathway by Taurine from Lycium barbarum (Goji Berry) in Human Retinal Pigment Epithelial Cells: Potential Benefit in Diabetic Retinopathy.Risk factors associated with retinal neovascularization of diabetic retinopathy in type 2 diabetes mellitus.Biomarkers for Diabetic Retinopathy - Could Endothelin 2 Be Part of the Answer?Ozagrel attenuates early streptozotocin-induced constriction of arterioles in the mouse retina.Awareness and practices on eye effects among people with diabetes in rural Tamil Nadu, India.Attenuation of diabetes-induced retinal vasoconstriction by a thromboxane receptor antagonist.Anti-inflammatory therapy for diabetic retinopathy.Inflammation and diabetic retinal microvascular complications.Nerve growth factor in diabetic retinopathy: beyond neurons.Increase in retinal hypoxia-inducible factor-2α, but not hypoxia, early in the progression of diabetes in the rat.Diabetic complications in the cornea.Characterisation of human non-proliferative diabetic retinopathy using the fractal analysis.Nerve growth factor protects against palmitic acid-induced injury in retinal ganglion cells.Imbalance of the Nerve Growth Factor and Its Precursor: Implication in Diabetic Retinopathy.Retinal blood flow abnormalities following six months of hyperglycemia in the Ins2(Akita) mouse.Metabolomics window into diabetic complications.
P2860
Q31107637-93C4A60C-8B90-4AF0-9F04-BC9C408B9DA2Q33634756-0D7E0B66-1205-414F-B192-A527A9D1E801Q33665353-183187C1-05F3-457A-9270-4135491FB80CQ33867982-F6AFDE6A-DD5F-4209-A62B-159FBA48AA7CQ34996605-3AC9C6A3-670A-4734-BA11-195907A11DB0Q35234189-E9D28494-637A-4613-BD77-833DD9BAC1E8Q35903992-40EAF976-6AF3-4FDA-A980-EFA91F14E5E9Q35923906-B26C7B92-E207-4439-8F3D-26DCAF70C28CQ36092355-D3F60FBB-16EB-46BA-8E5B-9702B78F1E7FQ36646301-67529935-B0AE-40B9-A936-56BCBA2B13FCQ37025311-03648A05-C6DF-473E-BAFA-73A481481ECEQ37096956-C97C6A52-8A8E-40B0-A2ED-D81DF9CF8E44Q37873482-7A57BA46-F617-4546-BC92-07671BAF4124Q37911285-DB547108-5820-4EAB-AA88-B1F4EE68726DQ38230380-5E8D134E-C7BF-4357-9E88-742A96362172Q38585336-D3201190-AC7E-454B-A3CA-C51F9A07C8C8Q39238815-498DA899-5BB1-466C-BE50-6195D30C7801Q40308351-BED11719-8377-470A-8F6C-2CDE9151F778Q40463678-534AD03C-B5DD-4772-B14E-DD0C397F148DQ41839716-DFFE0CB2-F78B-43C6-9C41-126A257ADDEAQ42141781-EF31A203-F583-459F-9A8E-9636249A78F4Q48286659-F155D867-2EFD-4841-969D-97E12DB58403
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Update on the treatment of diabetic retinopathy.
@ast
Update on the treatment of diabetic retinopathy.
@en
Update on the treatment of diabetic retinopathy.
@nl
type
label
Update on the treatment of diabetic retinopathy.
@ast
Update on the treatment of diabetic retinopathy.
@en
Update on the treatment of diabetic retinopathy.
@nl
prefLabel
Update on the treatment of diabetic retinopathy.
@ast
Update on the treatment of diabetic retinopathy.
@en
Update on the treatment of diabetic retinopathy.
@nl
P1476
Update on the treatment of diabetic retinopathy
@en
P2093
Alvin K H Kwok
Jason C S Yam
P577
2007-02-01T00:00:00Z